UK Markets close in 37 mins
  • FTSE 100

    7,225.87
    +8.34 (+0.12%)
     
  • FTSE 250

    23,006.86
    -47.23 (-0.20%)
     
  • AIM

    1,237.05
    -2.85 (-0.23%)
     
  • GBP/EUR

    1.1864
    +0.0012 (+0.10%)
     
  • GBP/USD

    1.3822
    +0.0028 (+0.2018%)
     
  • BTC-GBP

    48,407.68
    +3,187.49 (+7.05%)
     
  • CMC Crypto 200

    1,551.60
    +70.80 (+4.78%)
     
  • S&P 500

    4,537.14
    +17.51 (+0.39%)
     
  • DOW

    35,617.17
    +159.86 (+0.45%)
     
  • GOLD FUTURES

    1,782.50
    +12.00 (+0.68%)
     
  • NIKKEI 225

    29,255.55
    +40.03 (+0.14%)
     
  • HANG SENG

    26,136.02
    +348.81 (+1.35%)
     
  • DAX

    15,527.85
    +12.02 (+0.08%)
     
  • CAC 40

    6,712.59
    +42.74 (+0.64%)
     

Global Liquid Biopsy Markets 2021-2025 - Instruments Key to Market Share & Bioinformatics Plays a Role

·5-min read

Dublin, Oct. 12, 2021 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Markets by Cancer Type and by Usage Type with Impact of COVID-19 Pandemic. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2021-2025" report has been added to ResearchAndMarkets.com's offering.

The Screening, Diagnostic, Therapy Selection, Recurrence Monitoring and Screening Market Potential are all explored in this report. What is the impact of the COVID pandemic on the Liquid Biopsy market? This report provides a detailed analysis.

Circulating Tumor Cells? Cell-Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and pitfalls. Understand growth expectations and the ultimate potential market size.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread screening for all types of cancers with a blood test.

GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The company is now working on a 10,000-plus subject study, called the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market.

New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has just moved out of the development phase and into the growth phase.

The impact on the health care industry is enormous. The report forecasts the market size out to 2024. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.

Liquid Biopsy Recent Developments

  • Liquid Biopsy NGS Panels - Diverse Test Claims

  • CMS Colon Cancer Screening Memo Bodes Well for Assays

  • Natera Liquid Biopsy Test Coverage to Expand

  • Freenome Closes Financing to Support Early Cancer Detection Trial

  • C$2.6M Liquid Biopsy Initiative

  • NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy

  • Liquid Biopsy Shows Promise as Screen for Cancers

  • Inivata launches RaDaRT for the detection of residual disease and recurrence

  • Liquid Biopsy Assay Detects 50+ Types of Cancer

  • Liquid Biopsy Study Confirms Concordance with Tissue Biopsy

  • Guardant Health Liquid Biopsy Expands Medicare Coverage

  • Aethlon Medical Lands Grant for Exosome Isolation Device

  • Biolidics to Develop Liquid Biopsy Breast Cancer Test

  • Liquid Biopsy Equal to Tissue to Indicate Immunotherapy Response

  • Exact Sciences buys Genomic Health

  • Multi-Gene Liquid Biopsy Breast Cancer Panel

  • Bio-Techne receives FDA breakthrough device for prostate cancer liquid biopsy

  • Thrive to Develop Earlier Detection of Multiple Cancer Types

  • Guardant Health Liquid Biopsy Test to be Covered by EviCore

  • Liquid biopsy combines Illumina's 'ultradeep' sequencing with Grail's machine learning

  • Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services

  • Natera Commercializes Tumor Whole Exome Sequencing from Plasma

  • Sienna Buys Liquid Biopsy & Exosome Isolation Technology

  • Inivata Completes £39.8M Series B Funding Round

  • Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance

  • CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials

  • Biodesix Acquires Integrated Diagnostics

  • Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx

  • Bio-Techne to Acquire Exosome Dx for Up to $575M

  • GRAIL Announces Data on Detection of Early-Stage Lung Cancers

  • Precision for Medicine Acquires ApoCell

  • NeoGenomics to Acquire Genoptix for Cash, Stocks

  • PGDx Liquid Biopsy Assay to be Used in Cancer Drug Study

  • Liquid Biopsy IDs More NSCLC Mutations in Study of Guardant Test

  • Inivata Gets Draft Medicare Coverage Determination for Lung Cancer Test

Market Trends

Factors Driving Growth

  • Non Invasive Game Changer

  • Lower Cost

  • Greater Accuracy

  • Wide Range of Potential Uses

  • Aging Population

Factors Limiting Growth

  • Lower prices

  • Lack of Standards

  • Protocol Resistance

  • Initial Adoption Cost

  • COVID-19

Instrumentation and Automation

  • Instruments Key to Market Share

  • Bioinformatics Plays a Role

Diagnostic Technology Development

  • Next Generation Sequencing Fuels a Revolution

  • Impact of NGS on pricing

  • Pharmacogenomics Blurs Diagnosis and Treatment

  • CGES Testing, A Brave New World

  • Biochips/Giant magnetoresistance based assay

Profiles of Key Players

  • Abbott Diagnostics

  • AccuraGen Inc

  • Acuamark Diagnostics

  • Admera Health, LLC

  • Agena Bioscience, Inc

  • Agilent

  • Amoy Diagnostics Co., Ltd

  • Anchor Dx

  • ANGLE plc

  • ApoCell, Inc

  • ArcherDx, Inc

  • Asuragen

  • AVIVA Biosciences

  • Baylor Miraca Genetics Laboratories

  • Beckman Coulter, Inc.

  • Becton, Dickinson and Company

  • BGI Genomics Co. Ltd

  • Bioarray Genetics

  • Biocartis

  • Biocept, Inc

  • Biodesix Inc

  • BioFluidica

  • bioMerieux Diagnostics

  • Bioneer Corporation

  • Bio-Rad Laboratories, Inc

  • Bio-Techne

  • Bioview

  • Bolidics

  • Boreal Genomics

  • Caris Molecular Diagnostics

  • CellMax Life

  • Cepheid (now Danaher)

  • Chronix Biomedical

  • Circulogene

  • Clinical Genomics

  • Cynvenio

  • Cytolumina Technologies Corp

  • CytoTrack

  • Datar Cancer Genetics Limited

  • Diagenode Diagnostics

  • Diagnologix LLC

  • Enzo Life Sciences, Inc

  • Epic Sciences

  • Epigenomics AG

  • Eurofins Scientific

  • Exosome Diagnostics

  • Exosome Sciences

  • Fluidigm Corp

  • Fluxion Biosciences

  • Foundation Medicine

  • Freenome

  • GeneFirst Ltd.

  • Genetron Health (Beijing) Co., Ltd

  • Genomic Health

  • GILUPI Nanomedizin

  • Grail, Inc

  • Guardant Health

  • HansaBiomed

  • HeiScreen

  • Helomics

  • Horizon Discovery

  • iCellate

  • Illumina

  • Incell Dx

  • Inivata

  • Integrated Diagnostics

  • Janssen Diagnostics

  • MDNA Life SCIENCES, Inc

  • MDx Health

  • Menarini Silicon Biosystems

  • Millipore Sigma

  • Miltenyi Biotec

  • miR Scientific

  • Molecular MD

  • Myriad Genetics/Myriad RBM

  • NantHealth, Inc

  • Natera

  • NeoGenomics

  • New Oncology

  • Novogene Bioinformatics Technology Co., Ltd

  • Oncocyte

  • OncoDNA

  • Oxford Nanopore Technologies

  • Perkin Elmer

  • Personal Genome Diagnostics

  • PrecisionMed

  • Promega

  • Qiagen Gmbh

  • Quidel

  • Rarecells SAS

  • RareCyte

  • Resolution Biosciences, Inc

  • Roche Molecular Diagnostics

  • Screencell

  • Siemens Healthineers

  • simfo GmbH

  • Singlera Genomics Inc

  • SRI International

  • Sysmex Inostics

  • Tempus Labs, Inc

  • Thermo Fisher Scientific Inc

  • Thrive Earlier Detection

  • Trovagene

  • Volition

For more information about this report visit https://www.researchandmarkets.com/r/8fyvuw

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting